 ROCKVILLE, MD, Dec. 18, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc. The research collaboration will incorporate MacroGenics proprietary DART platform to enable simultaneous targeting of two undisclosed targets in a therapeutic area outside oncology. 